Therapies and treatments are becoming more specialized, and decisions on product acceptance and reimbursement are increasingly tied to effective communication of product value. Pharmaceutical, medical technology and life sciences companies need to generate a variety of insights to convince health insurers, doctors and patients of the product's value. 

Market Access describes the entire process from the comprehensive and forward-looking development of an overall cross-market strategy to the operational and proactive implementation in a complex and evolving environment with a seemingly simple goal: to give as many patients as possible access to innovative products at a fair price.

To achieve this, IPF GmbH supports this endeavor by generating a comprehensive evidence base regarding the epidemiological environment, the clinical and economic value of its technology to reimbursement bodies, health budget managers, investors and ultimately prescribing physicians.

We offer the following services in this area:

• Development of an HTA Market Access Evidence Roadmap for medicinal products, medical devices and digital health applications.
• Support with the entire application process for the drug reimbursement procedure at the umbrella organization of the Austrian social insurance institutions together with our renowned cooperation partner KWPC - Krammer, Wrbka & Partner Consulting GmbH.
• Determination of the target population for medicinal products, medical devices and digital health applications
• Quantification of the additional benefit .
• Adaptation of global cost-utility models, cost-effectiveness models and budget impact models.
• Development of cost-utility models, cost-effectiveness models and budget impact models.
• Conducting model validations with local experts to increase local evidence. 
• Publication of results in peer-reviewed journals or as poster presentations.